Enovis Stock Price, News & Analysis (NYSE:ENOV)

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings or view top-rated stocks.

5 equities research analysts have issued twelve-month price targets for Enovis' shares. Their ENOV share price targets range from $62.00 to $75.00. On average, they expect the company's stock price to reach $67.83 in the next year. This suggests a possible upside of 39.2% from the stock's current price.
View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts.

Enovis' stock was trading at $53.52 at the beginning of the year. Since then, ENOV shares have decreased by 8.9% and is now trading at $48.7350.
View the best growth stocks for 2023 here.

Enovis saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,610,000 shares, an increase of 11.4% from the October 15th total of 3,240,000 shares. Based on an average daily volume of 553,400 shares, the days-to-cover ratio is currently 6.5 days. Approximately 7.3% of the company's shares are short sold.
View Enovis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ENOV earnings forecast.

Enovis Co. (NYSE:ENOV) posted its earnings results on Tuesday, November, 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.02. The firm had revenue of $417.50 million for the quarter, compared to the consensus estimate of $414.89 million. Enovis had a positive trailing twelve-month return on equity of 3.70% and a negative net margin of 4.51%. Enovis's quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the company posted $0.59 EPS.

ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Value ETF (RFV) and Dimensional US Small Cap Value ETF (DFSV).iShares U.S. Medical Devices ETF (IHI).

Enovis issued an update on its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $2.30-2.40 for the period, compared to the consensus EPS estimate of $2.32.

Enovis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Diamond Hill Capital Management Inc. (4.45%), DAVENPORT & Co LLC (3.06%), Channing Capital Management LLC (2.30%), Allspring Global Investments Holdings LLC (1.88%), American Century Companies Inc. (1.59%) and Principal Financial Group Inc. (1.53%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends.

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.